Concomitant Infection of Intestinal Parasites and Helicobacter Pylori

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-30

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intestinal parasitic infections such as Giardia lamblia, Entamoeba histolyica and Enterobius Vermicularis are among the most common infections worldwide.So parasitic infections are considered one of the major health problems in the world especially in developing countries.

Helicobacter pylori is a gram-negative,helical-shaped,motile bacillus bacterium,which colonizes the gastric mucosa.

H.pylori bacterium secretes urease,a special enzyme that converts urea to ammonia.

Ammonia reduces the stomach's acidity .This risk factor allows pathogenic intestinal protozoa such as G.lamblia to take the opportunity to cross through the stomach's increased pH and cause disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy

NCT05329636

Helicobacter Pylori Infection

RECRUITING PHASE1/PHASE2

Pathogen-microbiome Interaction During Helicobacter Pylori Infection

NCT05121025

Helicobacter Pylori Infection

RECRUITING

Phenotypic and Genotypic Variations of Enterococcus Spp

NCT05751317

Isolation of Enterococci From Samples Demonstration of Enterococci Antibiotic Susceptibility Detection of Strains Enterococci Produce Biofilm +3 more

UNKNOWN

Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers

NCT03270800

Helicobacter Pylori Infected Subjects Helicobacter Pylori Naive Subjects

COMPLETED PHASE1

Existence in the Human Digestive Flora of Phages Able to Prevent the Acquisition of Multiresistant Enterobacteria

NCT03231267

Multiresistant Enterobacteriaceae

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspepsia Abdominal Burning Pain Diarrhea Dysentery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

100 positive stool samples for H.pylori

H.pylori stool antigen rapid test and stool parasitological examination

Intervention Type DIAGNOSTIC_TEST

200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done

B

100 negative stool samples for H.pylori

H.pylori stool antigen rapid test and stool parasitological examination

Intervention Type DIAGNOSTIC_TEST

200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H.pylori stool antigen rapid test and stool parasitological examination

200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients complaining of dyspepsia , abdominal burning pain,diarrhea,dysentery,of persons of any age or sex group.

Exclusion Criteria

* patients taking antibiotics within the previous four weeks, proton pump inhibitors within the previous two weeks, or anti-parasitic drugs within the previous two weeks.

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes